Cook Medical recently released the second generation of the 2.6 Fr CXI Support Catheter with platinum-iridium marker bands....
Intralink-Spine, Inc. (ILS) announces the expansion of clinical trials in Australia for their patented medical device for the treatment of low back pain, called Réjuve™. “We’re pleased that Dr. Rosenberg and his staff are participating in the GEMS clinical study for low back pain,”...
Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders...
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) today announced availability of the FDA-approved generic version of EpiPen Jr®1 (epinephrine injection, USP) Auto-Injector, ...
Medtronic and Edwards Lifesciences received good news last week as the FDA approved the use of their TAVR heart-valve replacement systems for use in lower risk, healthier patients....
Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease (PAD and CAD)...
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company focused on the development of therapeutics for human aging, reported financial and operating results for the second quarter ended June 30, 2019....
Life Spine, a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today that they are continuing in their efforts to revolutionize spine surgery...
Concept Medical Inc. (CMI) has been granted "Breakthrough Device Designation" from the U.S. Food and Drug Administration (FDA) for MagicTouch PTA (Percutaneous Transluminal Angioplasty), its Sirolimus drug coated balloon (DCB) catheter, for the treatment of Peripheral Artery Disease (PAD) in Below-the-Knee (BTK)....
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the European Commission (EC) has approved variations to broaden the use of Imbruvica® (ibrutinib) in two indications. This includes the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukaemia...